FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 248 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Popular Fitness Instructor Encourages Others to Maintain Routine Check Ups After... February 9, 2021 Identification of Actionable Molecular Alterations in NCI-MATCH November 2, 2020 Baby Boy Can’t Stop Smiling After Surgery Allows Him To See... September 18, 2019 Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas June 27, 2023 Load more HOT NEWS Proton and Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer Show Similar Late Effects, QoL,... EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of... EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin and Pembrolizumab Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors...
